ANI Pharmaceuticals Buys Alimera Sciences
Baudette, Minnesota-based drug manufacturer ANI Pharmaceuticals announced that it will acquire Alimera Sciences. ANI Pharmaceuticals will acquire Alimera with cash and financing, paying $5.50 per share — a 75% premium over Alimera’s previous close, plus as much as 50¢ per share more should the business hit revenue goals in 2026 and 2027. The transaction is valued at $381 million. Alimera Sciences is an Alpharetta, Georgia-based pharmaceutical company that develops and commercializes prescription ophthalmic retinal pharmaceuticals. Alimera has 160 employees globally and markets two products: Iluvien, which treats diabetic macular edema, and Yutiq, which treats chronic non-infectious... Read More »
Juvisé Pharmaceuticals Purchases Global Rights to PONVORY
On March 26, Juvisé Pharmaceuticals announced that it entered into an agreement to acquire the global rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson company. These global rights exclude the rights to United States and Canada. Ponvory is indicated for the treatment of adults with active forms of relapsing multiple sclerosis; it is protected by several patents, the latest of which expires in 2035. Founded in 2008, Juvise Pharmaceuticals is an international pharmaceutical company based in Villeurbanne, France. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry and rheumatology,... Read More »
Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion
On December 26, Bristol Myers Squibb (BMS) announced that it was entering a merger agreement to acquire RayzeBio, Inc. BMS will commence a tender offer to acquire all of the outstanding shares of RayzeBio common stock at a price of $62.50 per share in an all-cash transaction for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs. Current pipeline programs are targeting the treatment of solid tumors, including... Read More »
PE-Backed Laboratoire X.O Acquires nimodipine
Laboratoire X.O, backed by European mid-market private equity firm Stanley Capital Partners, announced on November 6 that it purchased nimodipine from Bayer AG, a German biopharmaceutical company. nimodipine is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage. nimodipine is sold and marketed under the brand name Nimotop. Laboratoire X.O is a pharmaceutical company that specializes in mature market authorizations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care and women’s health. It is based in Paris, France. The... Read More »
TenX Keane Acquires Citius Pharmaceuticals
On October 24, TenX Keane Acquisition, a special purpose acquisition company (SPAC), announced that it entered into an agreement with Citius Pharmaceuticals, Inc. to acquire Citius’ oncology subsidiary. The transaction is valued at $675 million. Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products. The company has a pipeline of anti-infectives in adjunct cancer care, stem cell therapy and unique prescription products. According to Citius’ financial reports, it did not generate any revenues for both years ended September 30, 2022 and September 30,2021. TenX is led by... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
